Cadila Pharmaceuticals, Helperby Therapeutics deal

Antibiotic company Helperby granted Cadila worldwide development and commercialization rights to HT61, an undisclosed topical compound that improves the efficacy of existing antibiotics against highly resistant bacteria. HT61 has completed a Phase II trial to treat nasal carriage of Staphylococcus aureus prior to hospitalization. Cadila expects to bring the first combination to market in about 18 months. The partners did not disclose financial terms. ...